Neuralink is a Healthcare Technology founded in 2016, currently valued at $9.7B. IPO Status: Pre-IPO (monitoring). IPO Readiness Score: 63/100 (C).
Neuralink IPO status, timeline, valuation and S-1 filing tracker. Last updated May 2026.
| Industry | Healthcare Technology |
| Stage | Series E |
| IPO Status | Private |
| Valuation | $9.7B |
| Total Funding | $1.3B |
| Headquarters | Austin, TX |
| IPO Readiness Score | 63/100 |
| Founded | 2016 |
Track Neuralink IPO status, valuation updates, and S-1 filing milestones on TechStackIPO. Last updated May 2026.
Brain-computer interface company developing implantable chips (Telepathy device). Raised $650M Series E at $9B valuation (June 2025). CEO Elon Musk has no IPO plans — company is focused on FDA clinical trials, not public markets.
Neuralink is currently a private company being monitored by TechStackIPO for potential IPO activity. The company’s IPO readiness score is 63/100. Companies in the Healthcare Technology sector have seen significant IPO activity in recent years, with several notable listings and S-1 filings tracked on TechStackIPO. Key factors that could accelerate Neuralink’s path to IPO include revenue growth, profitability milestones, favorable market conditions, and strategic investor interest.
Neuralink is valued at $9.7B based on the most recent private market data. The company has raised a total of $1.3B in funding. Private market valuations are determined by the latest funding round and may differ from eventual IPO pricing, which reflects public market conditions, investor demand, and comparable company multiples at the time of listing.
Accredited investors may be able to access Neuralink pre-IPO shares through secondary market platforms. These platforms facilitate private share transactions between existing shareholders (employees, early investors) and new buyers.
Risk factors: Pre-IPO investments are illiquid, carry higher risk than public market investments, and are typically restricted to accredited investors. Share availability and pricing depend on current shareholders willing to sell. TechStackIPO provides data and tracking tools but does not facilitate or recommend investments.
Neuralink has an IPO readiness score of 63/100 on TechStackIPO. A moderate readiness score suggests the company may be 2–4 years from IPO.
Neuralink's last known private valuation is $9.7B. IPO valuations typically reflect current market conditions at time of listing and may differ from private market valuations.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.
No. Neuralink has not yet filed an S-1 registration statement with the SEC as of TechStackIPO's latest data update.
Neuralink operates in the Healthcare Technology sector. TechStackIPO tracks multiple Healthcare Technology companies from seed through IPO, including their funding rounds, valuations, and IPO readiness scores. You can compare Neuralink against other Healthcare Technology companies using TechStackIPO's comparison tool.
Neuralink is at the Series E stage. The company has raised a total of $1.3B in funding. Companies at this funding stage are typically scaling operations, expanding market share, and evaluating public market timing.
Neuralink is headquartered in Austin, TX. The company's location can influence IPO exchange selection, regulatory requirements, and investor interest. Companies headquartered in major tech hubs often benefit from proximity to venture capital networks and talent pools.